Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ABBV-932: Arm A | Experimental | Participants will receive a single dose of ABBV-932 Arm A on day 1 under fasting conditions. |
|
| ABBV-932: Arm B | Experimental | Participants will receive a single dose of ABBV-932 Arm B on day 1 under fasting conditions. |
|
| ABBV-932: Arm C | Experimental | Participants will receive a single dose of ABBV-932 Arm C on day 1 under fasting conditions. |
|
| ABBV-932: Arm D | Experimental | Participants will receive a single dose of ABBV-932 Arm D on day 1 with a high-fat meal. |
|
| ABBV-932: Arm E | Experimental | Participants will receive a single dose of ABBV-932 Arm E on day 1 with a high-fat meal. |
|
| ABBV-932: Arm F | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABBV-932 | Drug | Oral Capsule |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of ABBV-932 | Cmax of ABBV-932 | Up to approximately 6 days |
| Time to Cmax (Tmax) of ABBV-932 | Tmax of ABBV-932 | Up to approximately 6 days |
| Terminal Phase Elimination Rate Constant (Beta) of ABBV-932 | Terminal phase elimination rate constant (beta) of ABBV-932 | Up to approximately 6 days |
| Terminal Phase Elimination Half-Life (t1/2) of ABBV-932 | Terminal phase elimination half-life of ABBV-932 | Up to approximately 6 days |
| Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932 | AUCt of ABBV-932 | Up to approximately 6 days |
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932 | AUCinf of ABBV-932 | Up to approximately 6 days |
| Number of Participants Experiencing Adverse Events | An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. | Up to approximately 180 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Acpru /Id# 266649 | Grayslake | Illinois | 60030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will receive a single dose of ABBV-932 Arm F on day 1 under fasting conditions.
|
| ABBV-932: Arm G | Experimental | Participants will receive a single dose of ABBV-932 Arm G on day 1 with a high-fat meal. |
|
| ABBV-932: Arm H | Experimental | Participants will receive a single dose of ABBV-932 Arm H on day 1 under fasting conditions. |
|
| ABBV-932 | Drug | Oral tablet |
|